Effect of Poor Glycemic Control with Length of Pulmonary Tuberculosis Treatment in Type 2 Diabetes Mellitus Patients
Abstract
Type 2 Diabetes Mellitus (T2DM) is one of the leading risk factors in developing Pulmonary Tuberculosis (PTB) and associated with a higher risk in recurrence, treatment failure, and MDR-TB. Duration of PTB treatment usually takes six months with first line regimen, however in uncontrolled blood glucose confirmed by HbA1c, Fasting Blood Glucose (FBG), and Postprandial Glucose (PPG) the treatment takes longer than usual because of the difficulty to achieve an optimal management in both diseases. The aim of this study was to assess the correlation between glycemic control and duration of anti-tuberculosis treatment at Persahabatan General Hospital, Jakarta in 2019-2021. It was a non-experimental study with analytical observational design and retrospective approach by using medical records. Data were analyzed descriptively and by the chi square method. Odds ratio and relative risk measure the association between duration of treatment in PTB patients and their gylcemic controls. The results showed that 57 PTB patients with T2DM (69.5%) received nine months course of anti-tuberculosis therapy. Most patients tend to have poor glycemic control shown by HbA1c level >7% (79.3%), FBG >130 mg/dL (72%), and PPG >180 mg/dL (80.5%). Correlation between glycemic control and duration of PTB treatment are significant shown by p-value result 0,001. The OR result was found to be 8.74 (95% CI 2.45-31.11) which indicate that patients with poor glycemic control have a greater risk to experience longer duration of PTB treatment. In conclusion, duration of PTB treatment are mostly done in more than six months due to poor glycemic control.
Keywords
Full Text:
PDFReferences
Setiati S, Alwi I, Sudoyo A, Simadibrata M, Setiyohadi B, Syam A. Buku Ajar Ilmu Penyakit Dalam. VI. Setiati S, editor. Jakarta: Interna Publishing; 2014. 883–863 p.
Silva DR, Muñoz-Torrico M, Duarte R, Galvão T, Bonini EH, Arbex FF, et al. Definition, Classification and Diagnosis of Diabetes, Prediabetes and Metabolic Syndrome. Kementeri Kesehat Republik Indones [Internet]. 2018;53(9):80. Available from: https://www.researchgate.net/ publication/334255803_Kendali_ Glikemik_pada_Pasien_Diabetes_ Melitus_Tipe_2_dengan_dan_tanpa_ Tuberkulosis_Paru
Kementerian Kesehatan RI. Laporan Riskesdas 2018. Lap Nas Riskesdas 2018 [Internet]. 2018;53(9):154–65. Available from: http://www.yankes. kemkes.go.id/assets/downloads/PMK No. 57 Tahun 2013 tentang PTRM.pdf
Pranoto A, Studi P, Jenjang K, Fakultas D, Universitas K, Epidemiologi D, et al. Kendali Glikemik pada Pasien Diabetes Melitus Tipe 2 dengan dan tanpa Tuberkulosis Paru Glycemic Control in Type 2 Diabetes Mellitus Patients with and without Pulmonary Tuberculosis. J MKMI [Internet]. 2019;15(1):99–109. Available from: https://www.researchgate.net/ publication/334255803_Kendali_ Glikemik_pada_Pasien_Diabetes_ Melitus_Tipe_2_dengan_dan_tanpa_ Tuberkulosis_Paru
Kementrian Kesehatan Republik Indonesia. Pengobatan Pasien Tuberkulosis. Kementeri Kesehat Republik Indones [Internet]. 2017;1– 117. Available from: http://www.ljjkesehatan.kemkes.go.id/pluginfile.php/4607/coursecat/description/ Pengobatan Pasien TB.pdf
Soelistijo SA, Novida H, Rudijanto A, Soewondo P, Suastika K, Manaf A et al. Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 di Indonesia. Perkeni. 2019. 133 p.
Tenny S, Hoffman MR. Odds Ratio. [Updated 2023 May 22]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm. nih.gov/books/NBK431098/
Kemenkes RI. Konsensus Pengelolaan Tuberkulosis dan Diabetes melitus (TBDM) di Indonesia. 2015. p. 51.
Yoo JE, Kim D, Han K, Rhee SY, Shin DW, Lee H. Diabetes Status and Association with Risk of Tuberculosis among Korean Adults. JAMA Netw Open. 2021;4(9):1–11. 10. Siddiqui AN, Khayyam KU, Sharma M. Effect of Diabetes Mellitus on Tuberculosis Treatment Outcome and Adverse Reactions in Patients Receiving Directly Observed Treatment Strategy in India: A Prospective Study. Biomed Res Int. 2016;2016(Dm).
Punthakee Z, Goldenberg R, Katz P. Definition, Classification and Diagnosis of Diabetes, Prediabetes and Metabolic Syndrome. Can J Diabetes. 2018;42:S10–5.
Khalil NH, Ramadan RA. Study of risk factors for pulmonary tuberculosis among diabetes mellitus patients. Egypt J Chest Dis Tuberc [Internet]. 2016;65(4):817– 23. Available from: http://dx.doi. org/10.1016/j.ejcdt.2016.05.009
Susilawati made dewi, Muljati S. Hubungan Antara Intoleransi Glukosa dan Diabetes Melitus dengan Riwayat Tuberkulosis Paru Dewasa di Indonesia (Analisis Lanjut Riskesdas 2013). Media Litbangkes. 2016;26(9):71–6. 14. Niazi AK, Kalra S. Diabetes and tuberculosis: A review of the role of optimal glycemic control. J Diabetes Metab Disord. 2012;11(1):1.
Soelistijo SA, Lindarto D, Decroli E, Permana H, Sucipto KW, Kusnadi Y et. al. Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 di Indonesia 2021. 2021;46.
Putra ON, Hardiyono H, Rizkiyah F, Yuniar N.H A. Impact of Uncontrolled HbA1C on The Outcome of Tuberculosis Treatment in TB Patients With Diabetes. J Profesi Med J Kedokt dan Kesehat. 2020;14(2):210–20.
Wijaya I. CONTINUING MEDICAL EDUCATION Tuberkulosis Paru pada Penderita Diabetes Melitus. Cdk-229. 2015;42(6):412–7.
Sari WDP, Nurmainah, Untari EK. INTERAKSI OBAT HIPOGLIKEMIA ORAL (OHO) DENGAN OBAT ANTITUBERKULOSIS (OAT) PADA PASIEN DIABETES MELITUS TIPE 2 YANG TERINFEKSI TB PARU. Tanjungpura Univ J. 2020;14–6.
Wang JY, Lee MC, Shu CC, Lee CH, Lee LN, Chao KM, et al. Optimal duration of anti-TB treatment in patients with diabetes: Nine or six months? Chest [Internet]. 2015;147(2):520–8. Available from: http://dx.doi.org/10.1378/ chest.14-0918
DOI: https://doi.org/10.15416/ijcp.2023.12.1.1
Refbacks
- There are currently no refbacks.
Indonesian Journal of Clinical Pharmacy is indexed by
